Results 121 to 130 of about 672,318 (344)

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies [PDF]

, 2016
Acknowledgments This work was supported by The Croatian Science Foundation grant No. IP-2014-09-9730 (“Tau protein hyperphosphorylation, aggregation, and trans-synaptic transfer in Alzheimer’s disease: cerebrospinal fluid analysis and assessment of ...
Babić Leko, Mirjana, Bažadona, Danira, Buée, Luc, de Silva, Rohan, Delalle, Ivana, Giovanni, Giuseppe Di, Harrington, Charles, Hof, Patrick R., Jovanov-Milošević, Nataša, Wischik, Claude, Wray, Selina, Šimić, Goran   +11 more
core   +3 more sources

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani, Tsuyoshi Nakai, Yasuhiro Maeda, Reiko Ohdake, Atsuhiro Higashi, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Kazuya Kawabata, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe   +11 more
wiley   +1 more source

The Role of Natural Products in Pharmacotherapy of Alzheimer’s Disease [PDF]

, 2003
Alzheimer’s disease is characterized by forgetfulness, disturbance in memory and loss of mental abilities. The final outcome of the disease is loss of personality and intellectual functions.
Singh, Amrit Pal
core   +1 more source

Additional file 6: of Beneficial effects of curtailing immune susceptibility in an Alzheimerâ s disease model

, 2019
Figure S6. Negative controls for Fig. 8, panel a (Aβ1â 42 expression). Negative controls are reported in all panels marked with acronyms of secondary antibodies labeled with, respectively, Texas Red (TR) (PDF 455 kb)
Benedetto, Giulia Di, Burgaletto, Chiara, Carta, Anna, Saccone, Salvatore, Lempereur, Laurence, Mulas, Giovanna, Loreto, Carla, Bernardini, Renato, Cantarella, Giuseppina   +8 more
openaire   +1 more source

Plasma p‐tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Plasma p‐tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p‐tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Giulia Giacomucci, Assunta Ingannato, Chiara Crucitti, Silvia Bagnoli, Elisa Marcantelli, Sonia Padiglioni, Valentina Moschini, Carmen Morinelli, Laura Falsini, Sandro Sorbi, Valentina Berti, Benedetta Nacmias, Valentina Bessi   +12 more
wiley   +1 more source

Quick assessment for systematic test statistic inflation/deflation due to null model misspecifications in genome-wide environment interaction studies.

PLoS ONE, 2019
Gene-environment (GxE) interaction is one potential explanation for the missing heritability problem. A popular approach to genome-wide environment interaction studies (GWEIS) is based on regression models involving interactions between genetic variants ...
Masao Ueki, Masahiro Fujii, Gen Tamiya, for Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium   +3 more
doaj   +1 more source

The effects of donepezil in Alzheimer's disease - Results from a multinational trial [PDF]

, 1999
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD).
Burns, A., Friedhoff, L. T., Gauthier, S., Hecker, J., Möller, Hans-Jürgen, Petit, H., Rogers, S. L., Rossor, M.   +7 more
core   +1 more source

Additional file 1: of Beneficial effects of curtailing immune susceptibility in an Alzheimerâ s disease model

, 2019
Figure S1. Effects of the treatment with an anti-TNFSF10 monoclonal antibody on the expression of GITR and FoxP3, as well as the anti-inflammatory protein IL-10 in the hippocampus of 3xTg-AD mice. Representative immunofluorescence images of hippocampi for GITR and FoxP3 expression and co-localization from the same animal groups as above (merge column ...
Benedetto, Giulia Di, Burgaletto, Chiara, Carta, Anna, Saccone, Salvatore, Lempereur, Laurence, Mulas, Giovanna, Loreto, Carla, Bernardini, Renato, Cantarella, Giuseppina   +8 more
openaire   +1 more source

Moyamoya Disease and the Risk of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by the progressive narrowing of arteries at the base of the brain, forming abnormal collateral vascular networks. While vascular parkinsonism is noted in MMD, its link to Parkinson's disease (PD) has not been explored.
Dallah Yoo, Jeong‐Yong Shin, Rugyeom Lee, Jiwon Cheon, Ji Hun Kim, Doeun Kim, Jae‐Kyung Won, In‐Hwan Oh, Yunjong Lee, Tae‐Beom Ahn   +9 more
wiley   +1 more source

Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles.

PLoS ONE, 2019
Alzheimer's disease (AD) affects millions of people and is a major rising problem in health care worldwide. Recent research suggests that AD could have different subtypes, presenting differences in how the disease develops.
Gerard Martí-Juan, Gerard Sanroma, Gemma Piella, Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium   +3 more
doaj   +1 more source